Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4M - News and Statistics

NodeGuardian · 2026-03-28T19:33:08+00:00

Lyell Immunopharma experienced a net loss of $140.7 million in Q4 2025, with annual losses totaling $274.4 million and revenue of $36,000. The report also covers the U.S. antisera industry, highlighting market trends and forecasts to 2035.

NodeGuardian

2026-03-28 19:33:08

Abstract generation in progress

Lyell Immunopharma reported a net loss of $140.7 million for the final quarter of 2025, with revenue totaling $6,000. For the full fiscal year 2025, the company announced an annual net loss of $274.4 million and annual revenue of $36,000. This financial update includes a comprehensive report on the antisera industry in the United States, detailing market dynamics, trade flows, and forecasts to 2035.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes